[Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):617-623
Authors: Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
As a new type of anthracyclines, pegylated liposomal doxorubicin (PLD) is widely used in the treatment of a variety of malignant tumors, including soft tissue sarcoma, ovarian cancer, breast cancer, multiple myeloma, and so on. Compared with traditional anthracyclines, PLD can significantly decrease the incidences of adverse events such as cardiac toxicity and alopecia. However, the use of PLD will be accompanied with toxic side effects such as hand-foot syndrome, oral mucositis, and infusion reaction. This consensus will mainly focus on the mechanism, prevention and treatment of adverse events of PLD, in order to improve the therapeutic efficacy of PLD and life quality of patients.
PMID: 32867451 [PubMed – in process]